

Presenter has no relevant financial or non-financial interest to disclose.

What are the treatment options in patients with disorders of consciousness?

Géraldine Martens, PT, PhD candidate

Coma Science Group

GIGA-Consciousness

University of Liège, Belgium

Neurorehabilitation Lab

Spaulding Rehabilitation Hospital

Harvard Medical School, Boston, USA

www.giga.ulg.ac.be

www.comascience.org



Specificities of therapeutic interventions for DOC patients

- **Absence of communication**
- Lack of interaction with their environment
- Severe motor disability (e.g., spasticity)
- Constantly bedridden
- Fatigability
- Aphasia, blindness, deaf, etc.



➔ No active rehabilitative interventions

« Hable con Ella »
Pedro Almodóvar




Pharmacological interventions

Pharmacological interventions


Drugs	Study (first author, year)	Number of patients and etiology	Diagnosis	Placebo control	Reported functional outcome
<i>Dopaminergic agents</i>					
Amantadine	Giacino (2012)	184 TBI	MCS/VS	Yes	
	Schnakers (2008)	1 anoxic	MCS	No	Positive
	Patrick (2006)	10 TBI	Low responsive level	No	No effect
	Hughes (2005)	123 TBI	Coma	NA	No effect
	Saniova (2004)	41 TBI	'Persistent unconsciousness'	NA	Positive
	Meythaler (2002)	35 TBI	MCS	Yes	Positive
Bromocriptine	Brahmi (2004)	4 intoxication	Coma	No	Positive
Levodopa	Matsuda (2003)	3 TBI	VS	No	Positive
<i>Nonbenzodiazepine sedative</i>					
Zolpidem	Cohen (2008)	1 anoxic	Lethargic	No	Positive
	Shames (2008)	1 anoxic	MCS	No	Positive
	Singh (2008)	1 TBI	MCS	No	No effect
	Brefel-Courbon (2007)	1 hypoxic	Akinetic mutism	Yes	Positive
	Clauss (2006)	2 TBI, 1 anoxic	VS	No	Positive
	Clauss (2000)	1 TBI	Semi-comatose	No	Positive
<i>GABA agonist</i>					
Baclofen	Sarà (2007)	1 non-TBI	VS	No	Positive

Amantadine

- Dopaminergic agent (Parkinson)
- Enteral administration, 6 weeks treatment (200mg/2*day)
- Side effects (seizure)



Giacino & Whyte et al, *N Engl J Med*, 2012



Schnakers et al, *J Neurol Neurosurg Psychiatry* 2008

Zolpidem

- GABAergic agent
- Enteral/oral administration (10mg)
- No side effects (sleep)
- 5% responders
dramatic effects!
- 20% (12/60) improved
behaviors after zolpidem but
in only 1 patient changed of
diagnosis (regained
functional communication)





Figure 1 - Significant decrease of CRS-R total scores (ranging from 0 to 23) after zolpidem intake (interquartile range represented by errors bars) in the entire sample (n=60).


Zolpidem

A. Brain metabolism in zolpidem responders

Zolpidem
> Placebo




N=3





Apomorphine

- Dopaminergic agent
- Subcutaneous administration (12h/day)
- Only case studies
- Side effects



Pharmacological treatments conclusion



- Only a few pharmacological treatments
- Side effects / habituation
- Next:
Apomorphine multimodal trial
Zolpidem responders phenotype

Treating Disorders of Consciousness With Apomorphine: Protocol for a Double-Blind Randomized Controlled Trial Using Multimodal Assessments




Central Thalamic Deep Brain Stimulation


Projections from intralaminar nuclei



Multidimensional scaling of thalamocortical connectivities




Scannell et al. 1999



Adapted from:
Posner and Raichle 1994, Munkle et al. 2000.


Striatum

Intralaminar nuclei “reconnections”
in spontaneous recovery from
“vegetative” unresponsive state



Laureys et al, *Lancet* 2000

Intralaminar nuclei stimulation
induces “recovery” from
minimally responsive state



Schiff et al, *Nature* 2007

- MCS \rightarrow emerged –
prolonged effects
- *sustained attention*
 - *intelligible words*
 - *functional objects use*

Deep Brain Stimulation conclusion

- DBS modulates specific cognitive and behavioral functions (arousal, functional limb movement, swallowing).
- Evidence of DBS carryover effects
- Limitations:
 - Strict inclusion criteria (e.g., no thalamic lesion)
 - Invasive
 - No randomized controlled study

Non-invasive brain stimulations

tDCS



tDCS single session

ARTICLES

tDCS in patients with disorders of consciousness

Sham-controlled randomized double-blind study

Crossover RCT (n=55)




MCS
n=30

- ➔ No adverse events
- ➔ Clinical improvement in MCS only
- ➔ 13/30 responders (5 >1y post-insult)

tDCS to unveil covert consciousness

- 67yo woman in UWS for 4 years after a subarachnoid hemorrhage
- Out of 7 standardized CRS-R she showed 1 localization to pain
- She demonstrated consistent response to command only after tDCS
- Neuroimaging exams were consistent with the diagnosis of MCS*



→ tDCS may facilitate motor execution of the command when cognitive functions are preserved

Neural correlates of responsiveness

Brain Stimulation 8 (2015) 1116–1123



ELSEVIER

Contents lists available at ScienceDirect

Brain Stimulation

journal homepage: www.brainstimjrn1.com




Clinical Response to tDCS Depends on Residual Brain Metabolism and Grey Matter Integrity in Patients With Minimally Conscious State



8 tDCS responders versus 13 tDCS non-responders

Aurore Thibaut^{a,*}, Carol Di Perri^{a,1}, Camille Chatelle^{b,c}, Marie-Aur lie Bruno^a, Mohamed Ali Bahri^d, Sarah Wannez^a, Andrea Piarulli^{a,e}, Claire Bernard^f, Charlotte Martial^a, Lizette Heine^a, Roland Hustinx^f, Steven Laureys^a


Regional brain metabolism




Neural correlates of responsiveness

Brain connectivity – theta band

8 tDCS responders




14 tDCS non-responders



Repeated tDCS

Double-blind crossover RCT (16 chronic minimally conscious pts)
5 sessions – 20 min prefrontal tDCS

➔ Active session: significant time evolution ($p < 0.001$)



Some patients responded after 1, 2 or 3 days of tDCS

↗ responders (9/16 – 56%) & ↗ duration of the effects (1 week)

Single stim: 43% responders – effect size : 0.38 versus 0.57

Repeated tDCS



Archives of Physical Medicine and Rehabilitation

journal homepage: www.archives-pmr.org

Archives of Physical Medicine and Rehabilitation 2014;95:283-9



ORIGINAL ARTICLE

Transcranial Direct Current Stimulation Effects in Disorders of Consciousness



Efthymios Angelakis, PhD,^{a,b} Evangelia Liouta, MSc,^{a,b} Nikos Andreadis, PhD,^a Stephanos Korfiatis, MD,^{a,b} Periklis Ktonas, PhD,^a George Stranjalis, MD, PhD,^{a,b} Damianos E. Sakas, MD, PhD^{a,b}

From the ^aHellenic Center for Neurosurgical Research "Prof. Petros Kokkalis," Athens; and ^bEvangelismos Hospital, Department of Neurosurgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

5 sessions over M1 or DFPLC
7 VS and 3 MCS - chronic
→ All MCS showed clinical improvement immediately after treatment

5 sessions over DFPLC
7 VS and 6 MCS - chronic
→ Moderate clinical effects
→ Changes of EEG background in patients who improved clinically


Journal of the Neurological Sciences 375 (2017) 464–470



Contents lists available at ScienceDirect

Journal of the Neurological Sciences

journal homepage: www.elsevier.com/locate/jns



Repeated transcranial direct current stimulation in prolonged disorders of consciousness: A double-blind cross-over study



Anna Estraneo^{a,*}, Angelo Pascarella^a, Pasquale Moretta^a, Orsola Masotta^a, Salvatore Fiorenza^a, Grazia Chirico^a, Emanuela Crispino^a, Vincenzo Loreto^a, Luigi Trojano^{a,b}

^a Neurorehabilitation Unit and Research Lab. for Disorder of Consciousness, Maugeri ICS, Telese Terme, Italy


^b Neuropsychology Lab., Dept. of Psychology, Second University of Naples, Caserta, Italy

Stimulating different brain regions


COMA

SCIENCE GROUP


Prefrontal




Precuneus



Motor



Multichannel frontoparietal



Group level: Prefrontal tDCS best area to target

Single-subject level: Patient's tailored montage


Thibaut et al, 2014, 2017

Huang et al, 2017

Martens et al, submitted, Thibaut et al, submitted

tDCS - mesocircuit


Prefrontal tDCS better than targeting other areas?



Clinical translation



- Feasibility of tDCS for daily use
 - By relatives/caregivers (20 sessions)
- 27 MCS patients completed the study – compliance: **93±14%**
 - No clinical effects
- 22 MCS patients received $\geq 80\%$ tDCS sessions
 - Significant effects & trend at 8-week follow-up – no AE



Pharmacological treatments

- Amantadine in TBI → other etiologies?
- Zoplidem – 5% → phenotype of responders
- Apomorphine → randomized clinical trials


DBS

- Promising but invasive & no randomized clinical trials

NIBS

- tDCS is safe in severely brain-injured patients
- **Prefrontal** tDCS → consistent clinical improvement
- Repeated tDCS → increase duration of the effects
→ increase number of responders
- Need patients' tailored montage based on individual brain lesions

THANK YOU



geraldine.martens@ulg.ac.be
gmartens@partners.org





James S. McDonnell Foundation



Additional slides

tDCS – diagnostic tool?




↗ LIS, EMCS & MCS & **4 VS/UWS**

Mesocircuit model




transcranial
Direct
Current
Stimulation




Repeated tDCS

16 patients in MCS (> 3months; 12 TBI; 47±16 y)

Treatment effect: delta CRS-R day 5 & day 12 (follow-up)




Effect size: 0.43




Effect size: 0.57

* p<0.05

Targeting other areas?



Precuneus: critical hub for consciousness



Laureys et al, Lancet Neurology, 2004




Anode: posterior parietal cortex
Cathode: right SOR

2mA; 20min

5 tDCS sessions

Active and sham – 5d washout

tDCS – Precuneus



Repeated stimulation of the posterior parietal cortex in patients in minimally conscious state: A sham-controlled randomized clinical trial


33 MCS >3 months post-insult
(57±11y; 20 TBI)

9 responders (27%)
Sub-acute > chronic

No effect at 5day follow-up

Effect size : 0.31

Delta CRS-R total score
(IQR – min/max)



□ tDCS
■ sham




tDCS – motor cortex

Motor cortex: common & efficient tDCS target

For patients with DOC?

- Immobilization, paresis...
- Improve behavioral responsiveness
- Covert consciousness



JFK COMA RECOVERY SCALE - REVISED ©2004										
Record Form										
Patient:	Date:									
AUDITORY FUNCTION SCALE										
4 - Consistent Movement to Command *										
3 - Reproducible Movement to Command *										
2 - Localization to Sound										
1 - Auditory Startle										
0 - None										
VISUAL FUNCTION SCALE										
5 - Object Recognition *										
4 - Object Localization: Reaching *										
3 - Visual Pursuit *										
2 - Fixation *										
1 - Visual Startle										
0 - None										
MOTOR FUNCTION SCALE										
6 - Functional Object Use †										
5 - Automatic Motor Response *										
4 - Object Manipulation *										
3 - Localization to Noxious Stimulation *										
2 - Flexion Withdrawal										
1 - Abnormal Posturing										
0 - None/Flaccid										
SPONTANEOUS MOTOR/VERBAL FUNCTION SCALE										
3 - Intelligible Verbalization *										
2 - Vocalization/Oral Movement										
1 - Oral Reflexive Movement										
0 - None										
COMMUNICATION SCALE										
2 - Functional: Accurate †										
1 - Non-Functional: Intentional *										
0 - None										
AROUSAL SCALE										
3 - Attention										
2 - Eye Opening w/o Stimulation										
1 - Eye Opening with Stimulation										
0 - Unarousable										
TOTAL SCORE										

Denotes emergence from MCS †
Denotes MCS *



tDCS – motor cortex

Motor cortex: common
& efficient tDCS target

For patients with DOC?

- Immobilization, paresis...
- Improve behavioral responsiveness
- Covert consciousness

Group level (n=10): no significant improvement (p=0.55; ES=0.10)

Single-subject level: 2 responders

Single stimulation & small sample size


JFK COMA RECOVERY SCALE - REVISED ©2004									
Record Form									
Patient:	Date:								
AUDITORY FUNCTION SCALE									
4 - Consistent Movement to Command *									
3 - Reproducible Movement to Command *									
2 - Localization to Sound									
1 - Auditory Startle									
0 - None									
VISUAL FUNCTION SCALE									
5 - Object Recognition *									
4 - Object Localization: Reaching *									
3 - Visual Pursuit *									
2 - Fixation *									
1 - Visual Startle									
0 - None									
MOTOR FUNCTION SCALE									
6 - Functional Object Use †									
5 - Automatic Motor Response *									
4 - Object Manipulation *									
3 - Localization to Noxious Stimulation *									
2 - Flexion Withdrawal									
1 - Abnormal Posturing									
0 - None/Flaccid									
SEMIMOTOR/VERBAL FUNCTION SCALE									
3 - Intelligible Vocalization *									
2 - Vocalization/Oral Movement									
1 - Oral Reflexive Movement									
0 - None									
COMMUNICATION SCALE									
2 - Functional: Accurate †									
1 - Non-Functional: Intentional *									
0 - None									
AROUSAL SCALE									
3 - Attention									
2 - Eye Opening w/o Stimulation									
1 - Eye Opening with Stimulation									
0 - Unarousable									
TOTAL SCORE									

Denotes emergence from MCS †
Denotes MCS *


Fronto-parietal multichannel tDCS

Frontoparietal network
External awareness network
Critical for consciousness recovery

→ Stimulation of the external awareness network bilaterally




- Hypometabolic areas
- Preserved areas



Fronto-parietal multichannel tDCS


46 patients with prolonged DOC. VS and MCS, TBI and non-TBI
4 anodes and 4 cathodes – 1mA; 20min
Single stimulation – active & sham
Behavioral & EEG assessments

- Group level: no improvement
1 mA not enough?
1 session not enough?
- 6 responders (13%) mostly TBI
- EEG in responders: increase in theta complexity after active tDCS - no changes after sham tDCS






Prognostic



tDCS

transcranial Direct Current Stimulation - tDCS


Prefrontal stimulation



2 electrodes (or more)
Weak electrical current (1-2mA)

→ *Membrane polarization*
Anode: ↗ excitability
Cathode: ↘ excitability

Motor stimulation




→ *Long term effects*
Neural excitability & plasticity (LTP-LTD)
Ion channels (Na^+ , Ca^{2+})
NMDA receptors



Neural correlates


- hypometabolic
 - preserved
- $p < 0.05$







Neural correlates

fMRI 16 chronic MCS – 6 tDCS responders



Fronto-parietal multichannels tDCS

Measure of complexity: LZW estimation per band and electrode
 Percentage of change = $(\text{Post_LZW} - \text{Pre_LZW}) / \text{Pre_LZW} * 100 \%$



LZW significantly decreases with tDCS under anodes, indicating that **complexity decreases with tDCS** in these bands
 → more structure in the data following tDCS?


tDCS – diagnostic tool?

tDCS & TMS

25 chronic DOC (12 VS/UWS; 10 MCS; 2 EMCS; 1 LIS)


Anode: OFC (Fpz) & cathode: Cz

TMS: MEP, RMT, ICI, ICF






What is consciousness?



Unresponsive Wakefulness Syndrome

Laureys et al., 2010



"There's nothing we can do... he'll always be a vegetable."


Laureys, Trends in Cognitive Sciences, 2005

Why tDCS in DOC?

- No severe adverse effects
- Modulates spontaneous neuronal activity
- Inexpensive
- Reliable sham condition (for research)
- Easy to administer (→ clinical translation)


Neural correlates

Grey matter atrophy – VBM



- More atrophic in responders
- More atrophic in non-responders
- Overlapping

Brain metabolism – PET-scan



- hypometabolic
- preserved